Literature DB >> 11569258

[Effect of amyxin--a domestic analog of tilorone--on characteristics of interferon and immune status of man].

E P Sel'kova1, T A Semenenko, N N Nosik, T I Iudina, M P Amarian, L A Lavrukhina, T N Pantiukhova, G Iu Tarasova.   

Abstract

The influence of amyxin, the Russian oral analog of tilorone, on the human interferon and immune status has been evaluated. As revealed by this investigation the administration of amyxin has produced a rise in the content of serum interferon, an increase in the capacity of leukocytes and lymphocytes for synthesizing alpha- and gamma-interferon, the activation of NK and phagocytizing cells of peripheral blood. No essential influence of amyxin on the amount of B and T lymphocytes, their subpopulations and the levels of the main classes of immunoglobulins has been established.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11569258

Source DB:  PubMed          Journal:  Zh Mikrobiol Epidemiol Immunobiol        ISSN: 0372-9311


  4 in total

1.  Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection.

Authors:  Sean Ekins; Mary A Lingerfelt; Jason E Comer; Alexander N Freiberg; Jon C Mirsalis; Kathleen O'Loughlin; Anush Harutyunyan; Claire McFarlane; Carol E Green; Peter B Madrid
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  A STING agonist preconditions against ischaemic stroke via an adaptive antiviral Type 1 interferon response.

Authors:  Nandini Kundu; Amit Kumar; Carlo Corona; Yingxin Chen; Sonia Seth; Saravanan S Karuppagounder; Rajiv R Ratan
Journal:  Brain Commun       Date:  2022-05-24

3.  Tilorone-Dihydrochloride Protects against Rift Valley Fever Virus Infection and Disease in the Mouse Model.

Authors:  Kendra N Johnson; Birte Kalveram; Jennifer K Smith; Lihong Zhang; Terry Juelich; Colm Atkins; Tetsuro Ikegami; Alexander N Freiberg
Journal:  Microorganisms       Date:  2021-12-31

4.  Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.

Authors:  Sean Ekins; Thomas R Lane; Peter B Madrid
Journal:  Pharm Res       Date:  2020-03-25       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.